Stock OXIS INTERNATIONAL, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Company OXIS International, Inc. Other OTC

Equities

US6918294025

Pharmaceuticals

End-of-day quote Other OTC
Other stock markets
- USD - Intraday chart for OXIS International, Inc.
03-26 GT Biopharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
02-01 GT Biopharma to Conduct 1-for-30 Reverse Stock Split; Shares Fall MT

Business Summary

GT Biopharma, Inc. specializes in the research and development of therapeutic products used primarily for the treatment of cancer and disorders of the central nervous system.

The group has a portfolio of 3 products in clinical development phase (GTB-3550, GTB-3650 and GTB-5550; treatment of leukemia and solid tumors).

Managers

Managers TitleAgeSince
Michael Breen CEO
 Chief Executive Officer 62 21-01-12
Manu Ohri DFI
 Director of Finance/CFO 67 22-02-17
Jeffrey Miller PRN
 Corporate Officer/Principal - 22-12-13

Members of the board

Members of the board TitleAgeSince
Charles Casamento BRD
 Director/Board Member 78 23-04-30
Bruce Wendel BRD
 Director/Board Member 70 20-11-10
Rajesh Shrotriya BRD
 Director/Board Member 79 21-01-12
Michael Breen CEO
 Chief Executive Officer 62 21-01-12

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 0 96,230 0 0 83.75 %
Stock B 1 1,380,633 1,236,812 ( 89.58 %) 0

Shareholders

NameEquities%Valuation
DekaBank Deutsche Girozentrale
79.21 %
1,093,645 79.21 % 4 M $
SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.
6.653 %
91,860 6.653 % 344 659 $
Armistice Capital LLC
5.252 %
72,511 5.252 % 272 061 $
Michael Breen
2.067 %
28,540 2.067 % 107 082 $
Vanguard Group, Inc. (Subfiler)
1.486 %
20,512 1.486 % 76 961 $
BMO Bank NA (Investment Management)
1.439 %
19,872 1.439 % 74 560 $
Bruce Wendel
0.8514 %
11,755 0.8514 % 44 105 $
Manu Ohri
0.8450 %
11,667 0.8450 % 43 775 $
Geode Capital Management LLC
0.8101 %
11,184 0.8101 % 41 962 $
BlackRock Institutional Trust Co. NA
0.7339 %
10,132 0.7339 % 38 015 $

Company contact information

GT Biopharma, Inc.

8000 Marina Boulevard Suite 100

94005, Brisbane

+415 919 4040

http://www.gtbiopharma.com
address OXIS International, Inc.

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Other Pharmaceuticals

Sector Other Pharmaceuticals

1st Jan change Capi.
NOVO NORDISK A/S Stock Novo Nordisk A/S
+31.37% 588B
JOHNSON & JOHNSON Stock Johnson & Johnson
-2.79% 364B
MERCK & CO., INC. Stock Merck & Co., Inc.
+20.41% 326B
ABBVIE INC. Stock AbbVie Inc.
+5.49% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+14.83% 239B
NOVARTIS AG Stock Novartis AG
+9.93% 210B
ROCHE HOLDING AG Stock Roche Holding AG
-6.95% 200B
AMGEN INC. Stock Amgen Inc.
+11.17% 167B
PFIZER, INC. Stock Pfizer, Inc.
+0.13% 161B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. GTBP Stock
  4. Stock
  5. Company OXIS International, Inc.
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
BENEFIT NOW